Premium
PSA velocity in conservatively managed BPH: Can it predict the need for BPH‐related invasive therapy?
Author(s) -
Mochtar Chaidir A.,
Kiemeney Lambertus A.L.M.,
Laguna M. Pilar,
Debruyne Frans M.J.,
de la Rosette Jean J.M.C.H.
Publication year - 2006
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20436
Subject(s) - medicine , urology , prostate disease , prostate , cancer
OBJECTIVE To study the value of PSA velocity (PSAV) to predict benign prostatic hyperplasia (BPH) progression in patients managed with α 1 ‐blockers or watchful waiting (WW). METHODS Nine hundred and forty two BPH patients treated with α 1 ‐blocker or WW were reviewed. PSAV was defined as: (PSA t −PSA b )/(t/12); where PSA t = PSA at time of follow‐up (t, in months), PSA b = PSA at baseline. PSA t was taken from the 1 year follow‐up visit or, if not present, from the next available visit with a maximum of 24 months. RESULTS Five hundred and ninety five patients (234 α 1 ‐blocker, 361 WW) were included in the analyses. PSAV range was −5.24 to 43.06 ng/ml/year in α 1 ‐blocker patients and −6.11 to 19.55 ng/ml/year in WW patients (median: 0.01 ng/ml/year). PSAV was stratified into tertiles (Stable/Decrease/Increase). There were no significant differences in retreatment‐free survival and the risk of BPH‐related invasive therapy between the tertiles in both treatment groups. CONCLUSIONS PSAV did not predict BPH progression in either α 1 ‐blocker treated patients or WW group. Prostate 66: 1407–1412, 2006. © 2006 Wiley‐Liss, Inc.